| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NOL7 |
| Uniprot No | Q9UMY1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-257 aa |
| 活性数据 | MVQLRPRASR APASAEAMVD EGQLASEEEE AEHGLLLGQP SSGAAAEPLE EDEEGDDEFD DEAPEELTFA SAQAEAREEE RRVRETVRRD KTLLKEKRKR REELFIEQKK RKLLPDTILE KLTTASQTNI KKSPGKVKEV NLQKKNEDCE KGNDSKKVKV QKVQSVSQNK SYLAVRLKDQ DLRDSRQQAA QAFIHNSLYG PGTNRTTVNK FLSLANKRLP VKRAAVQFLN NAWGIQKKQN AKRFKRRWMV RKMKTKK |
| 分子量 | 29.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人NOL7蛋白的3篇代表性文献的简要信息(注意：文献为虚拟示例，实际研究中请查阅真实数据库)：
---
1. **文献名称**: *"NOL7: A novel tumor suppressor gene in head and neck squamous cell carcinoma"*
**作者**: Smith A, et al.
**摘要**: 发现NOL7在头颈癌中作为肿瘤抑制因子，通过重组表达人NOL7蛋白证明其能够抑制肿瘤细胞增殖并促进凋亡，机制涉及核仁RNA代谢调控。
2. **文献名称**: *"Structural characterization and functional analysis of recombinant human NOL7 protein"*
**作者**: Lee J, et al.
**摘要**: 报道了在大肠杆菌中高效表达重组人NOL7蛋白，通过X射线晶体学解析其三维结构，揭示了与RNA结合相关的关键结构域，为分子机制研究奠定基础。
3. **文献名称**: *"NOL7 regulates vascular endothelial growth factor (VEGF) via p53-dependent pathways"*
**作者**: Chen H, et al.
**摘要**: 通过重组NOL7蛋白的体外实验，证明其通过激活p53信号通路抑制VEGF表达，进而调控肿瘤血管生成，为抗肿瘤治疗提供潜在靶点。
---
**提示**：实际文献可通过PubMed或Google Scholar搜索关键词“recombinant NOL7”或“NOL7 protein function”获取，部分研究可能涉及基因调控、癌症或核仁功能等领域。
NOL7. a human protein encoded by the *NOL7* gene (nucleolar protein 7), is localized to the nucleolus and plays critical roles in ribosome biogenesis and RNA metabolism. It contains two conserved domains: an N-terminal domain involved in protein interactions and a C-terminal domain with homology to the yeast ribosome assembly factor Utp20. NOL7 has been implicated in vascular biology and tumor suppression. Studies suggest it acts as a tumor suppressor by suppressing angiogenesis; its overexpression inhibits endothelial cell proliferation and tube formation. It interacts with nucleophosmin (NPM1) and promotes apoptosis under stress conditions.
Recombinant human NOL7 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) for functional studies. Its recombinant form enables investigations into its molecular mechanisms, including RNA-binding properties, protein interaction networks, and regulatory roles in nucleolar processes. Notably, *NOL7* is frequently downregulated in cancers, particularly head and neck squamous cell carcinomas, where its loss correlates with poor prognosis. Research on recombinant NOL7 aids in exploring its therapeutic potential, such as restoring its expression to inhibit tumor growth or sensitize cancer cells to chemotherapy. Structural and functional analyses of this 28-30 kDa protein continue to clarify its role in linking nucleolar functions to cellular stress responses and cancer pathways.
×
